CLT-28643

alpha5beta1-integrin inhibitor

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Glaucoma 11/01/2016 - "Administration of the integrin α5β1 inhibitor CLT-28643 has therapeutic potential as an adjunct to glaucoma surgery, possibly with a superior efficacy and tolerability compared with MMC when used at the optimal dose." 11/01/2016 - "Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery."
2.	Blister (Bulla) 11/01/2016 - "Efficacy was shown to be dose-dependent for the integrin inhibitor CLT-28643 for bleb area and survival, and the wound healing process. " 11/01/2016 - "Immunostaining showed that integrin α5β1 was highly expressed in the bleb at early time-points after surgery and that CLT-28643 inhibited this upregulation. " 11/01/2016 - "While 2-μg single injection of CLT-28643 improved bleb characteristics in a similar way as 10-μg administered by eye drops and MMC, repeated injections of 2 μg showed superior efficacy compared to MMC, with no corneal toxicity. "

1.	Integrins
2.	Ophthalmic Solutions (Eye Drops)